Diabetes drug januvia tested to boost immune attack on liver cancer
NCT ID NCT02650427
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This pilot study tested the safety of giving sitagliptin (Januvia) for three weeks to 14 liver cancer patients before they had surgery to remove their tumors. The idea is that sitagliptin might help immune cells get into the tumor and fight it better. The main goal was to check for side effects, not to see if the drug shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sitagliptin (Januvia)
- What this could lead to
- If it works, this could point toward a way to boost the immune system's ability to fight liver cancer after surgery.
- What could go wrong
- This is a very early, small Phase 1 safety study with only 14 people. It is not designed to prove the drug works against cancer, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pitié-Salpêtrière Hospital
Paris, 75013, France